August
04
 

Startling admissions in IVF journal

Some IVF patients are being offered risky, unsafe techniques which have not been developed with clinical trial and which offer dubious benefits, according to an extraordinary article in the journal Reproductive BioMedicine Online (RBO). Writing in the journal founded by Robert Edwards, who won  a Nobel Prize for developing IVF, two British scientists have made a devastating critique of the IVF industry. Rachel Brown and Joyce Harper, of University College London, say:

“In 1978, the first child conceived by IVF was born. In the following 33 years, numerous technologies and techniques have been developed ... However, these techniques have rarely been robustly tested and approved before they are routinely offered to infertile couples. In other cases, a development in our scientific understanding of a technique has failed to be quickly incorporated into clinical changes. This raises the concern that some of the techniques offered to some patients offer little or no benefit, and in the worse cases is not confirmed to be safe.”

Brown and Harper worry that even riskier techniques -- such as artifical gametes -- are being developed, yet scientists may not be ready to change their ways to put patient safety first and to use randomised trials to test safety and efficacy.

As an example of undue haste, they point at preimplantation genetic screening of embryos. There have been 11 randomised trials for this technique, some of which revealed serious limitations. However, say Brown and Harper, “This improved scientific knowledge has done little to slow the use of PGS, and despite the evidence from multiple RCT to suggest it is incapable of improving clinical outcomes, PGS continues to be routinely used in a clinical setting.”

The authors also hint that commercial considerations may play a role in the promotion of techniques before they have been proven safe and effective. “Although the same could be said for all areas of medicine, assisted reproductive technology in particular has developed a very strong commercial backing. It is therefore particularly important to ensure that all new technologies are adequately and rigorously tested for both safety and efficiency, ideally before being used clinically.”

Furthermore, there is a danger of hurting emotionally vulnerable patients: “some of the techniques offered to some patients offer little or no benefit, and in the worse cases [are] not confirmed to be safe. This is a particular concern as many of the techniques discussed here are often reserved for already vulnerable patients, such as those with recurrent IVF failure.” 

Rarely have such reservations about the progress of IVF appeared in a professional journal. This article, "The clinical benefit and safety of current and future assisted reproductive technology" is required reading for anyone interested in the ethical dimension of assisted reproduction.



This article is published by Michael Cook and BioEdge.org under a Creative Commons licence. You may republish it or translate it free of charge with attribution for non-commercial purposes following these guidelines. If you teach at a university we ask that your department make a donation. Commercial media must contact us for permission and fees. Some articles on this site are published under different terms.

comments powered by Disqus
 

 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed

 Best of the web

 Recent Posts
Deliberately infecting healthy patients still happens—ethically
28 May 2016
Big fallout from Little Sisters case
28 May 2016
Patients don’t know their life is ending – new study
28 May 2016
Landmark UK decision broadens scope of surrogacy
28 May 2016
Kiev becomes hub for international surrogacy market
28 May 2016